» Articles » PMID: 36276485

Long-term Outcome of the Endoscopic Submucosal Dissection of Early Gastric Cancer: A Comparison Between Patients with and Without Liver Cirrhosis

Overview
Journal Oncol Lett
Specialty Oncology
Date 2022 Oct 24
PMID 36276485
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer (GC) and liver cirrhosis (LC) have high incidence rates, particularly in Eastern Asia; however, the long-term clinical outcomes or recurrence of GC following endoscopic submucosal dissection (ESD) in patients with comorbid LC remain unclear. The present study aimed to compare the long-term efficacy and safety of ESD in patients with GC, with and without LC. Patients with early GC (EGC) who had underlying LC and underwent endoscopic treatment (LC-EGC group) were enrolled in the present study. In addition, patients with EGC without LC (non-LC-EGC group) were matched at a ratio of 1:3 via propensity score matching. The clinical outcomes and histopathological data of both groups were analyzed. No significant differences were observed in procedure type, complications [intraprocedural bleeding (11.8%) and perforation (0.0%)], en bloc resection rate (94.1%) and complete resection rate (100%) between the two groups. Multivariate Cox regression analysis demonstrated that procedure time was significantly associated with procedure-associated bleeding [adjusted hazard ratio (HR), 1.017; 95% confidence interval (CI), 1.001-1.032; P=0.033]. Furthermore, LC was significantly associated with cancer recurrence (adjusted HR, 5.482; 95% CI, 1.102-27.279; P=0.038). Taken together, the results of the present study suggest that endoscopic resection of EGC in patients with LC is an effective and safe treatment method. However, further studies are required to assess recurrence.

Citing Articles

Outcomes of endoscopic submucosal dissection in cirrhotic patients: First American cohort.

Pecha R, Ayoub F, Patel A, Muftah A, Wright M, Khalaf M World J Hepatol. 2024; 16(5):784-790.

PMID: 38818291 PMC: 11135272. DOI: 10.4254/wjh.v16.i5.784.


Endoscopic Submucosal Dissection for Treatment of Early-Stage Cancer or Precancerous Lesion in the Upper Gastrointestinal Tract in Patients with Liver Cirrhosis.

Tan Y, Qing Y, Liu D, Gong J J Clin Med. 2023; 12(20).

PMID: 37892646 PMC: 10607660. DOI: 10.3390/jcm12206509.

References
1.
Anti M, Armuzzi A, Gasbarrini G . Epithelial cell turnover and apoptosis. Ital J Gastroenterol Hepatol. 1999; 30 Suppl 3:S276-8. View

2.
Jang H, Kim J, Song H, Woo K, Kim M, Kae S . Clinical outcomes of patients with liver cirrhosis who underwent curative surgery for gastric cancer: a retrospective multi-center study. Dig Dis Sci. 2007; 53(2):399-404. DOI: 10.1007/s10620-007-9884-3. View

3.
Oka S, Tanaka S, Kaneko I, Mouri R, Hirata M, Kawamura T . Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc. 2006; 64(6):877-83. DOI: 10.1016/j.gie.2006.03.932. View

4.
Ogura K, Okamoto M, Sugimoto T, Yahagi N, Fujishiro M, Kakushima N . Efficacy and safety of endoscopic submucosal dissection for gastric cancer in patients with liver cirrhosis. Endoscopy. 2008; 40(5):443-5. DOI: 10.1055/s-2007-995650. View

5.
Choe W, Kim J, Park J, Kim H, Cho D, Lee S . Endoscopic Submucosal Dissection of Early Gastric Cancer in Patients with Liver Cirrhosis. Dig Dis Sci. 2017; 63(2):466-473. DOI: 10.1007/s10620-017-4814-5. View